A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)
Phase of Trial: Phase I/II
Latest Information Update: 17 Dec 2018
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary) ; Mifepristone
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2018 Planned End Date changed from 1 Aug 2018 to 1 Dec 2021.
- 06 Dec 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated